| dc.contributor.author | Lozada, Issiah | |
| dc.contributor.author | Huang, Bin | |
| dc.contributor.author | Stilgenbauer, Morgan | |
| dc.contributor.author | Beach, Travis | |
| dc.contributor.author | Qiu, Zihan | |
| dc.contributor.author | Zheng, Yaorong | |
| dc.contributor.author | Herbert, David E | |
| dc.date.accessioned | 2021-10-22T17:54:17Z | |
| dc.date.available | 2021-10-22T17:54:17Z | |
| dc.date.issued | 2020-04-20 | |
| dc.date.submitted | 2021-10-15T21:05:26Z | en_US |
| dc.identifier.citation | Dalton Transactions, 2020, 49, 6557-6560 | en_US |
| dc.identifier.uri | http://hdl.handle.net/1993/36060 | |
| dc.description.abstract | Phenanthriplatin is a leading preclinical anticancer Pt complex distinguished by a phenanthridine ligand that facilitates DNA-targeted covalent binding via intercalation. We report here that Pt(II) complexes incorporating phenanthridine into a chelating, multidentate ligand scaffold exhibit a superior in vitro therapeutic index compared with phenanthriplatin and cisplatin. | en_US |
| dc.description.sponsorship | Natural Sciences and Engineering Research Council of Canada (RGPIN-2014-03733) | en_US |
| dc.language.iso | eng | en_US |
| dc.publisher | Royal Society of Chemistry | en_US |
| dc.rights | open access | en_US |
| dc.subject | chemotherapeutics | en_US |
| dc.subject | Coordination Chemistry | en_US |
| dc.title | Monofunctional platinum(ii) anticancer complexes based on multidentate phenanthridine-containing ligand frameworks | en_US |
| dc.type | Preprint | en_US |
| dc.identifier.doi | 10.1039/D0DT01275K | |
| local.author.affiliation | Faculty of Science | en_US |
